Google
BNTX 株価分析 — Biontech SE (Healthcare >> Biotechnology)
BNTX に関するよくある質問
BNTXのPER（株価収益率）は？
Biontech SE（BNTX）は現在PER -818.13倍で取引されています。
BNTXのROE（自己資本利益率）は？
Biontech SEのROEは-6.72%です。
BNTXの配当利回りは？
Biontech SEの配当利回りは0.00%です。
BNTXの品質スコア（Quality Score）は？
当社のAIはBNTXの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BNTXは今が買い時ですか？
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BNTXはどのセクターに属しますか？
Biontech SEはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
BNTX AI Analysis Summary
Our AI summary for BNTX: Biontech SE (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of -818.13, ROE of -6.72%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 90.58
Price
-2.27
(-2.44%)
Day Change
|
|
|---|
BNTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 68 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 90.58 |
| PBV / Sector |
1.25 / 5.20
GOOD
|
| Earning Per Share | -4.85 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
12.34 / 1.22
|
| Average 1M Daily Value |
69.48 M
|
| Average 1W Daily Value |
76.22 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
52% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:34 |
| Symbol | BNTX |
| Name | BIONTECH SE |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 252.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 23,480.30 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: An der Goldgrube 12, Mainz, Germany, 55131
Phone: 49 6131 9084
Website: https://www.biontech.de
Employees: 7,807
Sector: Healthcare >> Biotechnology
Description: BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
